CRS/HIPEC improves survival in small bowel adenocarcinoma patients

A systematic review and meta-analysis of 746 patients revealed that cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) significantly enhances median overall survival to 32.3 months, compared to 14.5 months with systemic chemotherapy alone. In patients undergoing complete cytoreduction, the study reported a major morbidity rate of 20.7% and a mortality rate of 1.7% associated with CRS/HIPEC. These findings suggest that CRS/HIPEC may offer a viable treatment option for select patients with low-volume peritoneal carcinomatosis.